Articles On Adalta (ASX:1AD)

Title Source Codes Date
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Stockhead 1AD 4 days ago
Closing Bell: Blood plasma giant CSL bleeds out in front of entire ASX on Monday

  ASX200 dragged down by bad drugs The IT Sector is up 1.1pc, Healthcare is down about 3.2pc Small cap winners led by American Rare Earths and Appen   The benchmark was shot through the heart by CSL this morning leaving everything else in...

Stockhead 1AD 2 weeks ago
Countdown on to AdAlta trial results as biotech advances partner discussions

AdAlta AD-214 Phase I extension study results forecast for release at end of February Results crucial as AdAlta looks to advance partnering discussions to take asset to Phase II trial 1AD’s trademarked i-body platform advancing next genera...

Stockhead 1AD 2 weeks ago
AdAlta (ASX:1AD) – Webinar Presentation

  Tim Oldham, CEO and Managing Director, AdAlta (ASX:1AD) is a clinical stage biotechnology company using its i-body platform to discover and develop next generation protein therapeutics addressing drug targets that are challenging fot othe...

ShareCafe 1AD 3 months ago
In Case You Missed It: UAE agricultural deliveries and some Swedish lithium

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Stockhead 1AD 3 months ago
AdAlta’s latest results bolster safety profile and dose selection for primary asset, enhancing partnering, reducing Phase 2 trial risks

AdAlta’s AD-214 Phase 1 extension study interim data reinforce safety profile and dose selection Company preparing for partnering and Phase 2 trial of AD-214 into Idiopathic Pulmonary Fibrosis In the US ~40,000 people die annually from Id...

Stockhead 1AD 3 months ago
ASX Health Stocks: Painchek’s Europe patent accepted; and HeraMed signs deal with Telstra Health

PainChek’s European patent HeraMed signs deal with Telstra AdAlta announced interim Phase 1 results Avita lowers 2023 guidance PainChek’s European patent application accepted PainChek (ASX: PCK) announced that the European Patent Office...

Stockhead 1AD 3 months ago
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Stockhead 1AD 3 months ago
Closing Bell: ASX has best week ever… or at least since everything crashed last month. So… wait… damn you Friday!

ASX200 closes +1.13% higher Property stocks, Industrials and IT Sector gain more than 2% Small caps led by takeover target MCM   The Australian sharemarket has ended the first week of November with another stout performance, momentarily a...

Stockhead 1AD 4 months ago
AdAlta reports favourable patient tolerability after third dose in AD-214 extension study

AdAlta (ASX:1AD), a clinical-stage company developing novel protein and cell therapeutic products from its i-body platform, has announced that all healthy volunteers in its AD-214 Phase 1 extension study have now successfully receiv...

BiotechDispatch 1AD 4 months ago
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Stockhead 1AD 4 months ago
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Stockhead 1AD 5 months ago
In Case You Missed It: Visual spodumene and Covid clinical trials  

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Stockhead 1AD 5 months ago
Market Highlights: Wall Street slips, common mistakes in stock trading, and 5 ASX small caps to watch today

Aussie shares set to track Wall Street lower at the open CPI report will be the main focus this week What are the common mistakes for stock traders    Australian shares are poised to track Wall Street and open lower this morning. At 8am A...

Stockhead 1AD 5 months ago
AdAlta completes patient recruitment for AD-214 study to treat debilitating diseases

Clinical stage drug discovery company AdAlta (ASX: 1AD) has completed the recruitment of healthy volunteers to its Phase I extension study of lead candidate AD-214 to treat debilitating and fatal scarring diseases including idiopathic pulmo...

smallcaps.wpenginepowered.com 1AD 5 months ago
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead 1AD 5 months ago
Closing Bell: Minus Energy, the ASX benchmark and small cap indices had a silly day of depressing trade

  ASX 200, Small Ords and Emerging Co’s indices all close -0.8% in the red Only the Energy Sector finds some green Small caps led by teeny-tiny energy minnow CCE The Australian sharemarket dropped on Wednesday, dragged down by miners and...

Stockhead 1AD 5 months ago
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Stockhead 1AD 5 months ago
Check Up: Australian biotech sector continues to be a magnet for US investors

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Stockhead 1AD 6 months ago
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Stockhead 1AD 6 months ago
ASX Health Stocks: Mesoblast crashes 54pc after FDA says it needs more data for approval

Mesoblast plunged over 50pc after FDA response AdAlta progresses on Phase 1 extension study ResMed down 10pc on falling margins Mesoblast asked to provide more data by FDA Regenerative medicine company Mesoblast (ASX:MSB) was hammered do...

Stockhead 1AD 6 months ago
ASX Today: Stocks to watch on Friday

Futures predict the ASX will again open in the red as US earnings season continues on and US job data is soon to be revealed. Back home, local traders are holding out for the RBA’s latest statement on its monetary policy decision made th...

themarketherald.com.au 1AD 6 months ago
Market Highlights: Tech titans’ earnings results, and why August could be ‘boring but volatile’

Local shares are poised to extend losses on Friday Tech titans Apple, Amazon and Atlassian reported their quarterlies August could live up to its “very boring” historical reputation for the stock market   The ASX 200 is set to open lower...

Stockhead 1AD 6 months ago
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Stockhead 1AD 6 months ago
ASX July Winners: Easing inflation, AI, and an oil rally lure sidelined traders back to risky assets

The ASX was higher by around 2.5% in July The best sectors were Tech and Energy We look at the best and worst performing ASX stocks for the month For the month of July, most major indexes on the ASX rose by around 2.5%. Name % Change...

Stockhead 1AD 7 months ago
AdAlta releases new data on Phase 1 trial of AD-214 in Idiopathic Pulmonary Fibrosis

AdAlta (ASX:1AD) has released new data on the potential efficacy of AD-214 in humans with Idiopathic Pulmonary Fibrosis and other fibrotic diseases.

BiotechDispatch 1AD 7 months ago
TMH Market Close: ASX200 sees red

The ASX has ended the final day of the trading week firmly in the red. All sectors were down with IT stocks taking the biggest hit – falling more than two per cent. Today findings were released from the Royal Commission into Centrelin...

themarketherald.com.au 1AD 7 months ago
CLOSING BELL: Investors in pain as ASX falls 1.69% to 50-day low

The S&P ASX 200 closes 1.69% lower setting new 50-day low, with Emerging Companies index also falling Golden Deeps uncovers in-demand germanium and gallium at Nosib vanadium-copper-lead-silver discovery AdAlta announces new data pointi...

Stockhead 1AD 7 months ago
In Case You Missed It: Germanium and gallium lead the pack followed by new drug data and lithium

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead 1AD 7 months ago
Top 10 at 10: ASX stock jumps on the germanium, gallium bandwagon, gains 45pc

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead 1AD 7 months ago
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Stockhead 1AD 9 months ago
Orphan drug designation has a direct impact on drug pricing for these pharma players

Orphan diseases are those impacting less than 200,000 patients Orphan drug designation ensures an exclusivity period for pharma companies The average orphan drug in the US retails for US$7,000 per month   Rare or ‘Orphan’ diseases affect...

Stockhead 1AD 9 months ago
Top 10 at 10: Copper finds and impressive March quarter results

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead 1AD 10 months ago
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead 1AD 10 months ago
CRITERION: The ASX cancer fighters with a sting in their treatment tails

Amid the bombed-out biotech sector, early-stage developers of a new cancer immunotherapy have caught the eye of investors after some promising clinical news. These companies are working on so-called CAR-T therapies, which work by ‘superchar...

Stockhead 1AD 10 months ago
Webinar Recap – KKO, VRX, 1AD & KNO

ShareCafeWebinar Recap – KKO, VRX, 1AD & KNO Catch up on the full presentations from Kinetiko (ASX: KKO), VRX Silica (ASX: VRX), Adalta (ASX: 1AD) & Knosys (ASX: KNO) Webinar Recap – KKO, VRX, 1AD & KNOCompany News

ShareCafe 1AD 11 months ago
Adalta (ASX:1AD) – Webinar Presentation

ShareCafeAdalta (ASX:1AD) – Webinar Presentation Tim Oldham – CEO and Managing Director – AdAlta is a clinical stage biotechnology company using its i-body platform to discover and develop next generation protein therapeutics addressing dr...

ShareCafe 1AD 11 months ago
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Stockhead 1AD 1 year ago
Closing Bell: ASX drops, and a waste management stock gets takeover offer

The ASX 200 dropped 0.30% and the ASX XEC declined 0.20% Only 4 out of 11 sectors were higher, with Utilities leading the way Waste management company M8 Sustainable receives unsolicited takeover offer   The ASX 200 declined 0.30% today,...

Stockhead 1AD 1 year ago
AdAlta (ASX:1AD) welcomes Yuuwa as new substantial shareholders

AdAlta (1AD) welcomes two new investors associated via the Yuuwa Capital Venture Capital fund as substantial shareholders The company says support from Yuuwa and major shareholders has enabled AdAlta’s continued pipeline progress and has...

themarketherald.com.au 1AD 1 year ago
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Stockhead 1AD 1 year ago
ASX Health Stocks: MGC Pharma passes final hurdle before FDA submission; patents for Recce and AdAlta

MGC Pharma completes pre-clinical study on CimetrA Recce Pharma close to getting Aussie patent AdAlta gets second patent in Japan   MGC Pharma on track for FDA submission MGC Pharma (ASX:MXC) has completed the full pre-clinical rodents st...

Stockhead 1AD 1 year ago
AdAlta (ASX:1AD) receives second Japanese patent for AD-214

AdAlta (1AD) has been granted its second patent by the Japanese Patent Office for its lead program, AD-214 The company says the patent is a “valuable” addition as it will support the expansion of protected claims for AD-214 in Japan whic...

themarketherald.com.au 1AD 1 year ago
Market Highlights: Fed comments scare the market, and 5 ASX small caps to watch on Tuesday

The ASX will open marginally lower on Tuesday Overnight, Wall Street was mixed but turned negative after comments from US Fed policymakers Oil prices rose another 1pc   Aussie shares will open marginally lower this morning, and at 8am AED...

Stockhead 1AD 1 year ago
Top 10 at 10: Which lithium stock leads the winners list on Friday?

Stockhead’s Top 10 at 10, published shortly after 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the bigg...

Stockhead 1AD 1 year ago
How out of favour Biotech has a PR problem and could learn from Dr Karl

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Stockhead 1AD 1 year ago
ASX Biotech Stocks: HitIQ nabs landmark deal with Premier League for its concussion management tech

HitIQ has entered into a two-year deal with the Premier League for its concussion management tech Hearing-aid manufacturer Nuheara has been awarded two US patents Argentica Therapeutics moves to second escalated dose cohort for its stroke...

Stockhead 1AD 1 year ago
Market Highlights: US and Euro shares on six-day losing streak, and 5 ASX small caps to watch on Thursday

The ASX will open lower on Thursday US and European sharemarkets are on a six-day losing streak Minutes from FOMC show that Fed officials expect rates to remain high Local shares are set to open slightly lower on Thursday. At 8am AEST, th...

Stockhead 1AD 1 year ago
Check Up: Blood clots are a $55bn opportunity and these 2 ASX stocks are vying for a slice

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Stockhead 1AD 1 year ago
Dr Boreham’s Crucible: Is Vectus Biosystems about to become a VIP for takeover suitors?

As with almost every other drug developer on the planet, Vectus Biostsyems (ASX:VBS) co-founder Maurie Stang believes his fibrotic diseases outfit is of interest to potential, deep-pocketed partners. The difference is that given his life sc...

Stockhead 1AD 1 year ago